High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells

Current chemotherapies for T cell acute lymphoblastic leukemia (T-ALL) efficiently reduce tumor mass. Nonetheless, disease relapse attributed to survival of preleukemic stem cells (pre-LSCs) is associated with poor prognosis. Herein, we provide direct evidence that pre-LSCs are much less chemosensit...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Invest
Autori principali: Gerby, Bastien, Veiga, Diogo F.T., Krosl, Jana, Nourreddine, Sami, Ouellette, Julianne, Haman, André, Lavoie, Geneviève, Fares, Iman, Tremblay, Mathieu, Litalien, Véronique, Ottoni, Elizabeth, Kosic, Milena, Geoffrion, Dominique, Ryan, Joël, Maddox, Paul S., Chagraoui, Jalila, Marinier, Anne, Hébert, Josée, Sauvageau, Guy, Kwok, Benjamin H., Roux, Philippe P., Hoang, Trang
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2016
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5127686/
https://ncbi.nlm.nih.gov/pubmed/27797342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI86489
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi